Table 1 Characteristics of study participants

From: Metabolic markers in blood can separate prostate cancer from benign prostatic hyperplasia

 

Patients ( n =29) (mean, range)

Controls ( n =21) (mean, range)

P -value

Age (years)

65.8 (58–76)

62.6 (52–69)

0.119

BMI (kg m−2)

26.3 (18–34)

26.2 (21.0–40.4)

0.630

Prostate volume (ml)

39.6 (19–130)

48.7 (21–110)

0.082

PSA at diagnosis (ng ml−1)

11.6 (4.3–50.4)

1.2 (0.3–2.6)

8.498 × 10−9*

PSA of sample (ng ml−1)

14.81 (5.8–55.9)

1.51 (0.4–4.2)

2.263 × 10−9*

PCA3 (score)

67.0 (2–166)

56.6 (6–576)

0.003*

HDL (mmol l−1)

1.55 (0.7–2.23)

1.43 (0.7–2.01)

0.345

LDL (mmol l−1)

3.24 (1.51–5.53)

3.34 (2.42–4.96)

0.477

Triglycerides (mmol l−1)

1.11 (0.6–2.82)

1.62 (0.46–6.07)

0.011*

Cholesterol (mmol l−1)

5.28 (3.1–7.3)

5.46 (4.3–7.1)

0.602

Tumour Gleason score

7.0 (6–9)

NA

NA

  1. Abbreviations: BMI=body mass index; HDL=high-density lipoprotein; LDL=low-density lipoprotein; NA=not applicable; PSA=prostate-specific antigen.
  2. *P-values are from Wilcoxon testing. Prostate volume is measured by ultrasound.
Back to article page